SUSTAINED VIROLOGICAL RESPONSE IN HCV PATIENTS TREATED WITH DACLATASVIR plus SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN: A MULTICENTER, FIELD-PRACTICE EXPERIENCE

被引：0
|
作者：
Sacco, Rodolfo
Salomoni, Elena
Parodi, Sara
Gianni, Elena
Gragnani, Laura
Andreotti, Giovanni
Zignego, Anna Linda
Gattai, Riccardo
Vivaldi, Ilo
De Luca, Andrea
Bartolozzi, Dario
Cinelli, Roberta
Pozzi, Marco
Coco, Barbara
Tapete, Gherardo
Forte, Paolo
Puntili, Rachele
Ricciardi, Liana
Sani, Spartaco
Luchi, Sauro
Brunetto, Maurizia Rossana
Valoriani, Beatrice
Riccardi, Maria Piera
Nencioni, Cesira
Aquilini, Donatella
Nerli, Alessandro
Esperti, Francesco
Mazzotta, Francesco
Fabiani, Silvia
Menichetti, Francesco
Bresci, Giampaolo
Colombatto, Piero
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)33694-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1523
引用
收藏
页码：S1097 / S1097
页数：1
相关论文
共 50 条
  • [1] Sustained virological response in HCV patients treated with daclatasvir plus sofosbuvir, with or without ribavirin: a multicenter, field-practice experience
    Sacco, R.
    Salomoni, E.
    Parodi, S.
    Gianni, E.
    Gragnani, L.
    Andreotti, G.
    Brunetto, M. R.
    Zignego, A. L.
    Gattai, R.
    Vivaldi, I.
    De Luca, A.
    Bartolozzi, D.
    Cinelli, R.
    Pozzi, M.
    Coco, B.
    Tapete, G.
    Forte, P.
    Puntili, R.
    Ricciardi, L.
    Sani, S.
    Luchi, S.
    Valoriani, B.
    Riccardi, M. P.
    Nencioni, C.
    Aquilini, D.
    Nerli, A.
    Esperti, F.
    Mazzotta, F.
    Bresci, G.
    Colombatto, P.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S734 - S734
  • [2] SUSTAINED VIROLOGICAL RESPONSE IN HCV INFECTED DECOMPENSATED CIRRHOTIC PATIENTS TREATED WITH DACLATASVIR AND SOFOSBUVIR
    Tun, Kyaw Thet
    Win, Nang K. T.
    Kyaw, A. Mi Mi
    Lin, Sithu
    Maung, Moe Zaw
    Myint, Khin Thuzar
    Hlaing, Naomi Khaing Than
    HEPATOLOGY, 2019, 70 : 967A - 967A
  • [3] Comparison of Sustained Viral Response with Sofosbuvir Plus Ribavirin and Sofosbuvir Plus Daclatasvir
    Idrees, Hifza
    Bin Saeed, Saud
    Haider, Hammad
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2018, 12 (03): : 1120 - 1122
  • [4] Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
    Welzel, Tania M.
    Petersen, Joerg
    Herzer, Kerstin
    Ferenci, Peter
    Gschwantler, Michael
    Wedemeyer, Heiner
    Berg, Thomas
    Spengler, Ulrich
    Weiland, Ola
    van der Valk, Marc
    Rockstroh, Juergen
    Peck-Radosavljevic, Markus
    Zhao, Yue
    Jimenez-Exposito, Maria Jesus
    Zeuzem, Stefan
    GUT, 2016, 65 (11) : 1861 - 1870
  • [5] Daclatasvir plus sofosbuvir with or without ribavirin in patients with chronic HCV infection: interim analysis of a multicenter compassionate use program
    Welzel, T.
    Cornberg, M.
    Petersen, J.
    Herzer, K.
    Berg, T.
    Spengler, U.
    Rockstroh, J.
    Ingiliz, P.
    Wiegand, J.
    Jimenez-Exposito, M.
    Zeuzem, S.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 : 24 - 25
  • [6] Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis
    Wahid, Braira
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (12) : 2195 - 2197
  • [7] Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir plus interferon plus ribavirin and sofosbuvir plus daclatasvir plus ribavirin)
    Wahid, Braira
    Shami, Khadija
    Joiya, Salman A.
    Ozuyar, Sevilay E. G.
    Idrees, Muhammad
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (12) : 3868 - 3870
  • [8] An integrated safety analysis of daclatasvir plus sofosbuvir, with or without ribavirin, in patients with chronic HCV infection
    Landis, Charles S.
    Nelson, David R.
    Sulkowski, Mark S.
    Ruane, Peter J.
    Mills, Anthony M.
    Poordad, Fred
    Wyles, David L.
    Bhore, Rafia
    Ackerman, Peter
    Rana, Khurram
    Swenson, Eugene S.
    Noviello, Stephanie
    HEPATOLOGY, 2015, 62 : 565A - 565A
  • [9] On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir
    Kowdley, Kris V.
    Nelson, David R.
    Lalezari, Jacob P.
    Box, Terry
    Gitlin, Norman
    Poleynard, Gary
    Rabinovitz, Mordechai
    Ravendhran, Natarajan
    Sheikh, Aasim M.
    Siddique, Asma
    Bhore, Rafia
    Noviello, Stephanie
    Rana, Khurram
    LIVER INTERNATIONAL, 2016, 36 (11) : 1611 - 1618
  • [10] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
    G. Shiha
    R. Soliman
    M. ElBasiony
    A. A. Hassan
    N. N. H. Mikhail
    Hepatology International, 2018, 12 : 339 - 347
12345